6
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Primary Care Management of Asthma Exacerbations or Attacks: Impact of the COVID-19 Pandemic

      brief-report

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The COVID-19 pandemic has brought a renewed focus on appropriate management of chronic respiratory conditions with a heightened awareness of respiratory symptoms and the requirement for differential diagnosis between an asthma attack and COVID-19 infection. Despite early concerns in the pandemic, most studies suggest that well-managed asthma is not a risk factor for more severe COVID-related outcomes, and that asthma may even have a protective effect. Advice on the treatment of asthma and asthma attacks has remained unchanged. This article describes some challenges faced in primary care asthma management in adults and in teenagers, particularly their relevance during a pandemic, and provides practical advice on asthma attack recognition, classification, treatment and continuity of care. Acute attacks, characterised by increased symptoms and reduced lung function, are often referred to as exacerbations of asthma by doctors and nurses but are usually described by patients as asthma attacks. They carry a significant and underestimated morbidity and mortality burden. Many patients experiencing an asthma attack are assessed in primary care for treatment and continuing management. This may require remote assessment by telephone and home monitoring devices, where available, during a pandemic. Differentiation between an asthma attack and a COVID-19 infection requires a structured clinical assessment, taking account of previous medical and family history. Early separation into mild, moderate, severe or life-threatening attacks is helpful for continuing good management. Most attacks can be managed in primary care but when severe or unresponsive to initial treatment, the patient should be appropriately managed until transfer to an acute care facility can be arranged. Good quality care is important to prevent further attacks and must include a follow-up appointment in primary care, proactive regular dosing with daily controller therapy and an understanding of a patient’s beliefs and perceptions about asthma to maximise future self-management.

          Supplementary Information

          The online version contains supplementary material available at 10.1007/s12325-022-02056-x.

          Related collections

          Most cited references79

          • Record: found
          • Abstract: not found
          • Article: not found

          Covid-19: risk factors for severe disease and death

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Covid-19: a remote assessment in primary care

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.

              For most patients, asthma is not controlled as defined by guidelines; whether this is achievable has not been prospectively studied. A 1-year, randomized, stratified, double-blind, parallel-group study of 3,421 patients with uncontrolled asthma compared fluticasone propionate and salmeterol/fluticasone in achieving two rigorous, composite, guideline-based measures of control: totally and well-controlled asthma. Treatment was stepped-up until total control was achieved (or maximum 500 microg corticosteroid twice a day). Significantly more patients in each stratum (previously corticosteroid-free, low- and moderate-dose corticosteroid users) achieved control with salmeterol/fluticasone than fluticasone. Total control was achieved across all strata: 520 (31%) versus 326 (19%) patients after dose escalation (p < 0.001) and 690 (41%) versus 468 (28%) at 1 year for salmeterol/fluticasone and fluticasone, respectively. Asthma became well controlled in 1,071 (63%) versus 846 (50%) after dose escalation (p < 0.001) and 1,204 (71%) versus 988 (59%) at 1 year. Control was achieved more rapidly and at a lower corticosteroid dose with salmeterol/fluticasone versus fluticasone. Across all strata, 68% and 76% of the patients receiving salmeterol/fluticasone and fluticasone, respectively, were on the highest dose at the end of treatment. Exacerbation rates (0.07-0.27 per patient per year) and improvement in health status were significantly better with salmeterol/fluticasone. This study confirms that the goal of guideline-derived asthma control was achieved in a majority of the patients.
                Bookmark

                Author and article information

                Contributors
                Monica.Fletcher@ed.ac.uk
                Journal
                Adv Ther
                Adv Ther
                Advances in Therapy
                Springer Healthcare (Cheshire )
                0741-238X
                1865-8652
                14 February 2022
                14 February 2022
                : 1-17
                Affiliations
                [1 ]GRID grid.4305.2, ISNI 0000 0004 1936 7988, The Usher Institute, , University of Edinburgh, ; Edinburgh, UK
                [2 ]GRID grid.4494.d, ISNI 0000 0000 9558 4598, Department of General Practice and GRIAG Research Institute, , University Medical Center Groningen, University of Groningen, ; Groningen, The Netherlands
                [3 ]GRID grid.9757.c, ISNI 0000 0004 0415 6205, Department of Pharmacy and Bioengineering, , University of Keele, ; Keele, Staffordshire UK
                [4 ]GRID grid.418236.a, ISNI 0000 0001 2162 0389, Respiratory, , GlaxoSmithKline, ; Brentford, London, UK
                [5 ]Respiratory, General Medicines Emerging Markets, GlaxoSmithKline, Singapore, 139234 Singapore
                Author information
                http://orcid.org/0000-0002-9700-3552
                Article
                2056
                10.1007/s12325-022-02056-x
                8853035
                35157217
                4cbd5aca-73ab-43ed-9436-acad800bc24e
                © The Author(s) 2022

                Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

                History
                : 22 November 2021
                : 21 January 2022
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/100004330, GlaxoSmithKline;
                Categories
                Commentary

                asthma,attacks,exacerbations,management,pandemic,primary care
                asthma, attacks, exacerbations, management, pandemic, primary care

                Comments

                Comment on this article